Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Vistagen Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of VTGN: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders11293−19
Shares138.8M56.5M−82.3M (−59.3%)
Value$122.1M$9.13M−$113.0M (−92.5%)

New holders (17)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to VTGN in Q3 2022
InstitutionSharesValue% of portfolio
Two Sigma Advisers, LP234,400$36.0K0.00%
Virtu Financial LLC230,742$35.0K0.00%
Acadian Asset Management LLC186,416$28.0K0.00%
TKG Advisors, LLC134,860$21.0K0.02%
Advisors Capital Management, LLC65,000$10.0K0.00%
Jane Street Group, LLC68,156$10.0K0.00%
Two Sigma Securities, LLC58,096$9.00K0.00%
Neuberger Berman Group LLC56,617$9.00K0.00%
Balyasny Asset Management LLC34,596$5.00K0.00%
Ameriprise Financial Inc21,775$3.00K0.00%
MML Investors Services, LLC15,000$2.00K0.00%
Mariner, LLC12,841$2.00K0.00%
Cambridge Investment Research Advisors, Inc.10,531$2.00K0.00%
Sawtooth Solutions, LLC14,562$2.00K0.00%
Boyd Wealth Management, LLC12,180$2.00K0.00%
Twin Lakes Capital Management, LLC12,500$2.00K0.00%
Clear Street Markets LLC536$00.00%

Sold out (36)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.